| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:932-937.)
© 2004 American Heart Association, Inc.
Basic Science Reports |
From the Department of Surgery, Division of Cardiothoracic Surgery (J.J.Y., M.P.F., A.B., Y.I., D.S., H.L., A.A.) and Department of Pathology and Laboratory Medicine (J.J.Y., M.C.F., J.A.B.), University of California at Los Angeles, Los Angeles, Calif; Greater Los Angeles Veterans Administration Healthcare System (J.J.Y., A.A.), Los Angeles, Calif; and Serono Pharmaceutical Research Institute (A.E.I.P.), Geneva, Switzerland.
Correspondence to Abbas Ardehali, MD, Division of Cardiothoracic Surgery, CHS 62-182, UCLA Medical Center, 10833 Le Conte Ave, Los Angeles, CA 90095. E-mail aardehali{at}mednet.ucla.edu
Received October 3, 2003; de novo received July 24, 2004; revision received October 17, 2003; accepted October 21, 2003.
Background Chemokine-chemokine receptor interaction and the subsequent recruitment of T-lymphocytes to the graft are early events in the development of chronic rejection of transplanted hearts or cardiac allograft vasculopathy (CAV). In this study, we sought to determine whether blockade of chemokine receptors CCR1 and CCR5 with Met-RANTES affects the development of CAV in a murine model.
Methods and Results B6.CH-2bm12 strain donor hearts were transplanted heterotopically into wild-type C57BL/6 mice (myosin heavy chain II mismatch). Recipients were treated daily with either Met-RANTES or vehicle starting on postoperative day 4 and were euthanized on postoperative days 24 and 56. We found that Met-RANTES significantly reduced intimal thickening in this model of chronic rejection and that Met-RANTES markedly decreased the infiltration of CD4 and CD8 T lymphocytes and MOMA-2+ monocytes/macrophages into transplanted hearts. Met-RANTES also suppressed the ex vivo and in vitro proliferative responses of recipient splenocytes to donor antigens. Finally, Met-RANTES treatment was associated with a marked reduction in RANTES/CCL5 and monocyte chemoattractant protein-1 gene transcript levels in the donor hearts.
Conclusions Antagonism of the chemokine receptors CCR1 and CCR5 with Met-RANTES attenuates CAV development in vivo by reducing mononuclear cell recruitment to the transplanted heart, proliferative responses to donor antigens, and intragraft RANTES/CCL5 and monocyte chemoattractant protein-1 gene transcript levels. These findings suggest that chemokine receptors CCR1 and CCR5 play significant roles in the development of chronic rejection and may serve as potential therapeutic targets.
Key Words: transplantation lymphocytes rejection chemokine
This article has been cited by other articles:
![]() |
A. Schober Chemokines in Vascular Dysfunction and Remodeling Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1950 - 1959. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A Belperio and A. Ardehali Chemokines and Transplant Vasculopathy Circ. Res., August 29, 2008; 103(5): 454 - 466. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. T. Schnickel, S. Bastani, G. R. Hsieh, A. Shefizadeh, R. Bhatia, M. C. Fishbein, J. Belperio, and A. Ardehali Combined CXCR3/CCR5 Blockade Attenuates Acute and Chronic Rejection J. Immunol., April 1, 2008; 180(7): 4714 - 4721. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Choi, G. C. Hildebrandt, K. M. Olkiewicz, D. A. Hanauer, M. N. Chaudhary, I. A. Silva, C. E. Rogers, D. T. Deurloo, J. M. Fisher, C. Liu, et al. CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation Blood, November 1, 2007; 110(9): 3447 - 3455. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Mayer, K. L. Hudkins, F. Heller, H. Schmid, M. Kretzler, U. Brandt, H.-J. Anders, H. Regele, P. J. Nelson, C. E. Alpers, et al. Expression of the chemokine receptor CCR1 in human renal allografts Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1720 - 1729. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. van Loosdregt, M. F.M. van Oosterhout, A. H. Bruggink, D. F. van Wichen, J. van Kuik, E. de Koning, C. C. Baan, N. de Jonge, F. H.J. Gmelig-Meyling, and R. A. de Weger The Chemokine and Chemokine Receptor Profile of Infiltrating Cells in the Wall of Arteries With Cardiac Allograft Vasculopathy Is Indicative of a Memory T-Helper 1 Response Circulation, October 10, 2006; 114(15): 1599 - 1607. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Notohamiprodjo, R. Djafarzadeh, A. Mojaat, I. von Luttichau, H.-J. Grone, and P. J. Nelson Generation of GPI-linked CCL5 based chemokine receptor antagonists for the suppression of acute vascular damage during allograft transplantation Protein Eng. Des. Sel., January 1, 2006; 19(1): 27 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. F. Yang, D. W. Ho, C. K. Lau, C. T. Lam, C. T. Lum, R. T. P. Poon, and S. T. Fan Allograft inflammatory factor-1 (AIF-1) is crucial for the survival and pro-inflammatory activity of macrophages Int. Immunol., November 1, 2005; 17(11): 1391 - 1397. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Hildebrandt, K. M. Olkiewicz, S. Choi, L. A. Corrion, S. G. Clouthier, C. Liu, J. S. Serody, and K. R. Cooke Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation Blood, March 15, 2005; 105(6): 2249 - 2257. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |